These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 15129427)

  • 1. Immunological monitoring during combination of patient-oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancer.
    Noguchi M; Itoh K; Suekane S; Morinaga A; Sukehiro A; Suetsugu N; Katagiri K; Yamada A; Noda S
    Prostate; 2004 Jun; 60(1):32-45. PubMed ID: 15129427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patients.
    Noguchi M; Itoh K; Yao A; Mine T; Yamada A; Obata Y; Furuta M; Harada M; Suekane S; Matsuoka K
    Prostate; 2005 Apr; 63(1):1-12. PubMed ID: 15378520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low-dose estramustine in HLA-A24-positive patients with castration-resistant prostate cancer.
    Noguchi M; Uemura H; Naito S; Akaza H; Yamada A; Itoh K
    Prostate; 2011 Apr; 71(5):470-9. PubMed ID: 20878951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer.
    Noguchi M; Yao A; Harada M; Nakashima O; Komohara Y; Yamada S; Itoh K; Matsuoka K
    Prostate; 2007 Jun; 67(9):933-42. PubMed ID: 17440952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination.
    Noguchi M; Kobayashi K; Suetsugu N; Tomiyasu K; Suekane S; Yamada A; Itoh K; Noda S
    Prostate; 2003 Sep; 57(1):80-92. PubMed ID: 12886526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate.
    Mackler NJ; Dunn RL; Hellerstedt B; Cooney KA; Fardig J; Olson K; Pienta KJ; Smith DC
    Cancer; 2006 Jun; 106(12):2617-23. PubMed ID: 16691618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral estramustine therapy in serum chromogranin A-positive stage D3 prostate cancer patients.
    Zaky Ahel M; Kovacic K; Kraljic I; Tarle M
    Anticancer Res; 2001; 21(2B):1475-9. PubMed ID: 11396235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy of personalized peptide vaccination and low-dose estramustine phosphate for metastatic hormone refractory prostate cancer patients: an analysis of prognostic factors in the treatment.
    Noguchi M; Mine T; Yamada A; Obata Y; Yoshida K; Mizoguchi J; Harada M; Suekane S; Itoh K; Matsuoka K
    Oncol Res; 2007; 16(7):341-9. PubMed ID: 17518272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salvage immunotherapy with subcutaneous recombinant interleukin 2 (rIL-2) and alpha-interferon (A-IFN) for stage D3 prostate carcinoma failing second-line hormonal treatment.
    Maffezzini M; Simonato A; Fortis C
    Prostate; 1996 May; 28(5):282-6. PubMed ID: 8610053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic retrovirally transduced, IL-2- and IFN-gamma-secreting cancer cell vaccine in patients with hormone refractory prostate cancer--a phase I clinical trial.
    Brill TH; Kübler HR; von Randenborgh H; Fend F; Pohla H; Breul J; Hartung R; Paul R; Schendel DJ; Gansbacher B
    J Gene Med; 2007 Jul; 9(7):547-60. PubMed ID: 17514769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dramatic decline in prostate-specific antigen by withdrawal of estramustine phosphate in hormone refractory prostate cancer.
    Kobayashi M; Kuramoto H; Ota J; Fujimoto N
    Int J Urol; 2006 Jul; 13(7):1019-21. PubMed ID: 16882080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical evaluation of estramustine phosphate and vinblastine in patients with hormone-refractory prostate cancer].
    Awakura Y; Yamamoto M; Fukuzawa S; Itoh N; Nonomura M; Fukuyama T
    Hinyokika Kiyo; 2000 Jul; 46(7):449-52. PubMed ID: 10965448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dexamethasone did not suppress immune boosting by personalized peptide vaccination for advanced prostate cancer patients.
    Naito M; Itoh K; Komatsu N; Yamashita Y; Shirakusa T; Yamada A; Moriya F; Ayatuka H; Mohamed ER; Matsuoka K; Noguchi M
    Prostate; 2008 Dec; 68(16):1753-62. PubMed ID: 18767041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
    Miyake H; Hara I; Eto H
    BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hormonal chemotherapy for hormone-refractory prostate cancer].
    Nishimura K; Nakai Y; Shimizu K; Tokizane T; Arai Y; Inoue H; Takaha N; Nonomura N; Okuyama A; Kamoi K; Ukimura O; Miki T; Koide T; Ichikawa Y; Nishimura K; Sugao H; Yamaguchi S; Takatera H; Uchida K; Miura H
    Hinyokika Kiyo; 2002 Nov; 48(11):713-8. PubMed ID: 12512147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to vinorelbine with or without estramustine as second-line chemotherapy in patients with hormone-refractory prostate cancer.
    Nakabayashi M; Ling J; Xie W; Regan MM; Oh WK
    Cancer J; 2007; 13(2):125-9. PubMed ID: 17476141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral estramustine phosphate and oral etoposide for the treatment of hormone-refractory prostate cancer.
    Numata K; Miura N; Azuma K; Karashima T; Kasahara K; Nakatsuzi H; Hashine K; Sumiyoshi Y
    Hinyokika Kiyo; 2007 Feb; 53(2):99-104. PubMed ID: 17352158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of estramustine phosphate on hormone refractory prostate cancer].
    Tanaka M; Shiomi K; Hamano S; Suzuki N; Igarashi T; Murakami S; Shimazaki J
    Hinyokika Kiyo; 1997 Mar; 43(3):245-50. PubMed ID: 9127765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Intermittent oral hormonal chemotherapy using estramustine phosphate and etoposide for the treatment of hormone-refractory prostate cancer].
    Kimura M; Sasagawa T; Tomita Y; Katagiri A; Morishita H; Saito T; Tanikawa T; Kawasaki T; Saito K; Nishiyama T; Kasahara T; Hara N; Takahashi K
    Hinyokika Kiyo; 2003 Dec; 49(12):709-14. PubMed ID: 14978952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811.
    Kelly WK; Halabi S; Elfiky A; Ou SS; Bogart J; Zelefsky M; Small E;
    Cancer; 2008 Dec; 113(11):3137-45. PubMed ID: 18989865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.